Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone

@article{Lee2011AntiMullerianHA,
  title={Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone},
  author={Sanghoon Lee and Sinan Ozkavukcu and Elke Heytens and Fred Moy and Rose M. Alappat and Kutluk H Oktay},
  journal={Journal of Assisted Reproduction and Genetics},
  year={2011},
  volume={28},
  pages={651-656}
}
To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC). The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment. AMH and AFC had a stronger correlation with the total number of oocytes and the number… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Fertility preservation and breast cancer: a review

Ecancermedicalscience • 2015
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 28 references

ESHRE Special Interest Group for Reproductive Endocrinology— AMH Round Table: Anti-Mullerian hormone (AMH): what do we still need to know

A La Marca, FJ Broekmans, A Volpe, BC Fauser, NS. Macklon
Hum Reprod • 2009

Implementing a survivorship care plan for patients with breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 1 Excerpt

Similar Papers

Loading similar papers…